Management of bone metastases in cancer: A review

Secondary title: 
T2 - Critical Reviews in Oncology/Hematology
Short title: 
Management of bone metastases in cancer: A review
Authors: 
Selvaggi, G.
Scagliotti, G. V.
Volume: 
56
Start page: 
365-378
Annotations: 
Type D, Priority 5
Date: 
December
Year: 
2005
Accession number: 
2005531934
Database: 
EMBASE SR
Number: 
M1 - 3
Serial: 
1040-8428
Type of work: 
M3 - Review
ID: 
12000
DOI: 
http://dx.doi.org/10.1016/j.critrevonc.2005.03.011
Key words: 
anemia/si [Side Effect]
antineoplastic activity
arthralgia/si [Side Effect]
bone metastasis/di [Diagnosis]
bone metastasis/dt [Drug Therapy]
bone metastasis/rt [Radiotherapy]
bone metastasis/su [Surgery]
bone necrosis/si [Side Effect]
bone pain/dt [Drug Therapy]
bone pain/si [Side Effect]
bone scintiscanning
breast cancer/dt [Drug Therapy]
bronchospasm/si [Side Effect]
cancer chemotherapy
cancer radiotherapy
cancer survival
clinical trial
diagnostic accuracy
diagnostic procedure
diarrhea/si [Side Effect]
digestive system function disorder/si [Side Effect]
disease course
drug clearance
drug efficacy
drug half life
drug safety
dyspnea/si [Side Effect]
fever/si [Side Effect]
flu like syndrome/si [Side Effect]
human
hypercalcemia/co [Complication]
hypercalcemia/dt [Drug Therapy]
meta analysis
multiple myeloma/dt [Drug Therapy]
muscle weakness/si [Side Effect]
myalgia/si [Side Effect]
nausea/si [Side Effect]
nephrotoxicity/si [Side Effect]
pain
pathologic fracture/co [Complication]
peripheral edema/si [Side Effect]
positron emission tomography
prognosis
radiography
review
risk assessment
sclerosis/si [Side Effect]
spinal cord compression/co [Complication]
symptomatology
systematic review
thrombocytopenia/si [Side Effect]
alendronic acid/dt [Drug Therapy]
antineoplastic agent/ae [Adverse Drug Reaction]
antineoplastic agent/ct [Clinical Trial]
antineoplastic agent/cb [Drug Combination]
antineoplastic agent/cm [Drug Comparison]
antineoplastic agent/do [Drug Dose]
antineoplastic agent/dt [Drug Therapy]
antineoplastic agent/iv [Intravenous Drug Administration]
antineoplastic agent/po [Oral Drug Administration]
antineoplastic agent/pk [Pharmacokinetics]
antineoplastic agent/pd [Pharmacology]
bisphosphonic acid derivative/ae [Adverse Drug Reaction]
bisphosphonic acid derivative/ct [Clinical Trial]
bisphosphonic acid derivative/cb [Drug Combination]
bisphosphonic acid derivative/cm [Drug Comparison]
bisphosphonic acid derivative/do [Drug Dose]
bisphosphonic acid derivative/dt [Drug Therapy]
bisphosphonic acid derivative/iv [Intravenous Drug Administration]
bisphosphonic acid derivative/po [Oral Drug Administration]
bisphosphonic acid derivative/pk [Pharmacokinetics]
bisphosphonic acid derivative/pd [Pharmacology]
calcium/dt [Drug Therapy]
calcium/po [Oral Drug Administration]
clodronic acid/ae [Adverse Drug Reaction]
clodronic acid/ct [Clinical Trial]
clodronic acid/cm [Drug Comparison]
clodronic acid/do [Drug Dose]
clodronic acid/dt [Drug Therapy]
clodronic acid/po [Oral Drug Administration]
clodronic acid/pa [Parenteral Drug Administration]
clodronic acid/pk [Pharmacokinetics]
colecalciferol/dt [Drug Therapy]
colecalciferol/po [Oral Drug Administration]
docetaxel/dt [Drug Therapy]
ethylenediaminetetramethylenephosphonate sr 89/dt [Drug Therapy]
etidronic acid/dt [Drug Therapy]
etidronic acid re 186/dt [Drug Therapy]
ibandronic acid/ae [Adverse Drug Reaction]
ibandronic acid/ct [Clinical Trial]
ibandronic acid/do [Drug Dose]
ibandronic acid/dt [Drug Therapy]
ibandronic acid/iv [Intravenous Drug Administration]
ibandronic acid/po [Oral Drug Administration]
ibandronic acid/pd [Pharmacology]
lexidronam samarium sm 153/dt [Drug Therapy]
paclitaxel/cb [Drug Combination]
paclitaxel/dt [Drug Therapy]
pamidronic acid/ae [Adverse Drug Reaction]
pamidronic acid/ct [Clinical Trial]
pamidronic acid/cm [Drug Comparison]
pamidronic acid/dt [Drug Therapy]
pamidronic acid/iv [Intravenous Drug Administration]
pamidronic acid/pd [Pharmacology]
phosphate p 32
phosphorus 32/cm [Drug Comparison]
phosphorus 32/dt [Drug Therapy]
phosphorus 32/po [Oral Drug Administration]
phosphorus 32/pk [Pharmacokinetics]
radiopharmaceutical agent/ae [Adverse Drug Reaction]
radiopharmaceutical agent/cm [Drug Comparison]
radiopharmaceutical agent/dt [Drug Therapy]
radiopharmaceutical agent/pk [Pharmacokinetics]
rhenium 186/cm [Drug Comparison]
rhenium 186/dt [Drug Therapy]
rhenium 186/pk [Pharmacokinetics]
samarium 153/ae [Adverse Drug Reaction]
samarium 153/cm [Drug Comparison]
samarium 153/dt [Drug Therapy]
samarium 153/pk [Pharmacokinetics]
strontium 89/cm [Drug Comparison]
strontium 89/dt [Drug Therapy]
strontium 89/pk [Pharmacokinetics]
unclassified drug
yttrium citrate y 90
zoledronic acid/ae [Adverse Drug Reaction]
zoledronic acid/ct [Clinical Trial]
zoledronic acid/cb [Drug Combination]
zoledronic acid/cm [Drug Comparison]
zoledronic acid/dt [Drug Therapy]
zoledronic acid/iv [Intravenous Drug Administration]
zoledronic acid/pd [Pharmacology]
Types of evidence: 
Type D
Priorities of Care: 
Priority 5: Plan and do